English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 19 January 2022, 17:36 JST
Share:
    

Source: Eisai
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
Highest Ranked Global Pharmaceutical Company

TOKYO, Jan 19, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been listed in the 2022 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's sixth inclusion on the list. Ranked 32nd, Eisai was the highest ranking company among global pharmaceutical companies.

The Global 100 evaluates the sustainability of approximately 6,900 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year. The Global 100 is based on up to 24 key performance indicators covering ESG initiatives, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai received high evaluation particularly on clean revenue and investment* and maintenance of work environment that ensures safety and health of employees.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

*Sales revenue, R&D cost and investment for products such as medicines which are under equitable pricing strategies and included in the WHO Essentials Medicines Lists or used to treat any of in scope diseases, conditions and pathogens defined by the ATM Index Foundation.


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Thursday, 22 August 2024, 19:54 JST
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Wednesday, 14 August 2024, 9:59 JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Tuesday, 6 August 2024, 13:15 JST
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
Wednesday, 31 July 2024, 13:59 JST
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
Monday, 29 July 2024, 17:59 JST
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575